Peringatan Keamanan

Dihydroergocornine effect on fertility was tested in preclinical studies. The reported effect was a decreased weight gain in neonates.T194 Overdosing has also been reported to present effects of fall of blood pressure and a decrease in heart rate to 13 beats per minute.A32968 To know more about the pharmacokinetics please visit DB01049.

Dihydroergocornine

DB11273

small molecule approved

Deskripsi

Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects.A32962 It is an artificial derivative of the crude extract of ergot and later purified, ergocornine.A32964 The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid.A32965 Dihydroergocornine presents a formula of 9,10 alpha-dihydro-12'-hydroxy-2',5'alpha-bis(1-methylethyl)-ergotaman-3',6',18-trione.T190 It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to DB01049

Struktur Molekul 2D

Berat 563.699
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) To know more about the pharmacokinetics please visit [DB01049].
Volume Distribusi To know more about the pharmacokinetics please visit [DB01049].
Klirens (Clearance) No pharmacokinetic related to the clearance rate was found in current literature.

Absorpsi

Dihydroergocornine absorption in man after oral administration is very rapid when compared to the mixture or most of the components. The time to reach maximum plasma concentration or 0.57 ng-eq/ml is 1.4 hours. It presents an absorption half-life of 0.32 hours. The absorption percentage is of about 25% which corresponds to the registered absorption presented in the ergoloid mixture.T191 To know more about the pharmacokinetics please visit DB01049.

Metabolisme

The biotransformation of dihydroergocornine occurs via oxidation and cleavage of the proline in the peptide portion of the molecule as well as by the splitting of the amide bond yielding dihydrolysergic acid amide. Some of the derivate metabolites retain the essential ring structure of the ergot alkaloid.T192 To know more about the pharmacokinetics please visit DB01049.

Rute Eliminasi

When orally administered, dihydroergocornine is almost completely eliminated via feces. The urinary secretion accounts only for 2.5% of the administered dose. On the other hand, when administered intravenously, the renal excretion can account for approximately 10% of the administered dose.T191 To know more about the pharmacokinetics please visit DB01049.

Interaksi Obat

1051 Data
Phenytoin The metabolism of Dihydroergocornine can be increased when combined with Phenytoin.
Fosphenytoin The metabolism of Dihydroergocornine can be increased when combined with Fosphenytoin.
Valsartan Dihydroergocornine may decrease the antihypertensive activities of Valsartan.
Ramipril Dihydroergocornine may decrease the antihypertensive activities of Ramipril.
Reserpine Dihydroergocornine may decrease the antihypertensive activities of Reserpine.
Remikiren Dihydroergocornine may decrease the antihypertensive activities of Remikiren.
Torasemide Dihydroergocornine may decrease the antihypertensive activities of Torasemide.
Guanadrel Dihydroergocornine may decrease the antihypertensive activities of Guanadrel.
Olmesartan Dihydroergocornine may decrease the antihypertensive activities of Olmesartan.
Chlorthalidone Dihydroergocornine may decrease the antihypertensive activities of Chlorthalidone.
Nitroprusside Dihydroergocornine may decrease the antihypertensive activities of Nitroprusside.
Minoxidil Dihydroergocornine may decrease the antihypertensive activities of Minoxidil.
Treprostinil Dihydroergocornine may decrease the antihypertensive activities of Treprostinil.
Bendroflumethiazide Dihydroergocornine may decrease the antihypertensive activities of Bendroflumethiazide.
Prazosin Dihydroergocornine may decrease the antihypertensive activities of Prazosin.
Fosinopril Dihydroergocornine may decrease the antihypertensive activities of Fosinopril.
Trandolapril Dihydroergocornine may decrease the antihypertensive activities of Trandolapril.
Metolazone Dihydroergocornine may decrease the antihypertensive activities of Metolazone.
Benazepril Dihydroergocornine may decrease the antihypertensive activities of Benazepril.
Cyclothiazide Dihydroergocornine may decrease the antihypertensive activities of Cyclothiazide.
Candoxatril Dihydroergocornine may decrease the antihypertensive activities of Candoxatril.
Mecamylamine Dihydroergocornine may decrease the antihypertensive activities of Mecamylamine.
Moexipril Dihydroergocornine may decrease the antihypertensive activities of Moexipril.
Lisinopril Dihydroergocornine may decrease the antihypertensive activities of Lisinopril.
Metyrosine Dihydroergocornine may decrease the antihypertensive activities of Metyrosine.
Hydroflumethiazide Dihydroergocornine may decrease the antihypertensive activities of Hydroflumethiazide.
Cryptenamine Dihydroergocornine may decrease the antihypertensive activities of Cryptenamine.
Perindopril Dihydroergocornine may decrease the antihypertensive activities of Perindopril.
Candesartan cilexetil Dihydroergocornine may decrease the antihypertensive activities of Candesartan cilexetil.
Eprosartan Dihydroergocornine may decrease the antihypertensive activities of Eprosartan.
Chlorothiazide Dihydroergocornine may decrease the antihypertensive activities of Chlorothiazide.
Quinapril Dihydroergocornine may decrease the antihypertensive activities of Quinapril.
Telmisartan Dihydroergocornine may decrease the antihypertensive activities of Telmisartan.
Hydrochlorothiazide Dihydroergocornine may decrease the antihypertensive activities of Hydrochlorothiazide.
Trichlormethiazide Dihydroergocornine may decrease the antihypertensive activities of Trichlormethiazide.
Deserpidine Dihydroergocornine may decrease the antihypertensive activities of Deserpidine.
Pentolinium Dihydroergocornine may decrease the antihypertensive activities of Pentolinium.
Trimethaphan Dihydroergocornine may decrease the antihypertensive activities of Trimethaphan.
Diazoxide Dihydroergocornine may decrease the antihypertensive activities of Diazoxide.
Bretylium Dihydroergocornine may decrease the antihypertensive activities of Bretylium.
Terazosin Dihydroergocornine may decrease the antihypertensive activities of Terazosin.
Captopril Dihydroergocornine may decrease the antihypertensive activities of Captopril.
Epoprostenol Dihydroergocornine may decrease the antihypertensive activities of Epoprostenol.
Polythiazide Dihydroergocornine may decrease the antihypertensive activities of Polythiazide.
Cilazapril Dihydroergocornine may decrease the antihypertensive activities of Cilazapril.
Saprisartan Dihydroergocornine may decrease the antihypertensive activities of Saprisartan.
Spirapril Dihydroergocornine may decrease the antihypertensive activities of Spirapril.
Tienilic acid Dihydroergocornine may decrease the antihypertensive activities of Tienilic acid.
Debrisoquine Dihydroergocornine may decrease the antihypertensive activities of Debrisoquine.
Diethylnorspermine Dihydroergocornine may decrease the antihypertensive activities of Diethylnorspermine.
Temocapril Dihydroergocornine may decrease the antihypertensive activities of Temocapril.
Hexamethonium Dihydroergocornine may decrease the antihypertensive activities of Hexamethonium.
Trimazosin Dihydroergocornine may decrease the antihypertensive activities of Trimazosin.
Nicorandil Dihydroergocornine may decrease the antihypertensive activities of Nicorandil.
Rauwolfia serpentina root Dihydroergocornine may decrease the antihypertensive activities of Rauwolfia serpentina root.
Enalaprilat Dihydroergocornine may decrease the antihypertensive activities of Enalaprilat.
Angiotensin 1-7 Dihydroergocornine may decrease the antihypertensive activities of Angiotensin 1-7.
Imidapril Dihydroergocornine may decrease the antihypertensive activities of Imidapril.
BQ-123 Dihydroergocornine may decrease the antihypertensive activities of BQ-123.
Cicletanine Dihydroergocornine may decrease the antihypertensive activities of Cicletanine.
Dihydralazine Dihydroergocornine may decrease the antihypertensive activities of Dihydralazine.
Zofenopril Dihydroergocornine may decrease the antihypertensive activities of Zofenopril.
Guanoxan Dihydroergocornine may decrease the antihypertensive activities of Guanoxan.
Delapril Dihydroergocornine may decrease the antihypertensive activities of Delapril.
Vincamine Dihydroergocornine may decrease the antihypertensive activities of Vincamine.
Linsidomine Dihydroergocornine may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Dihydroergocornine may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Dihydroergocornine may decrease the antihypertensive activities of Tolonidine.
Endralazine Dihydroergocornine may decrease the antihypertensive activities of Endralazine.
Cadralazine Dihydroergocornine may decrease the antihypertensive activities of Cadralazine.
Cyclopenthiazide Dihydroergocornine may decrease the antihypertensive activities of Cyclopenthiazide.
Bietaserpine Dihydroergocornine may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Dihydroergocornine may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Dihydroergocornine may decrease the antihypertensive activities of Methoserpidine.
Guanoclor Dihydroergocornine may decrease the antihypertensive activities of Guanoclor.
Muzolimine Dihydroergocornine may decrease the antihypertensive activities of Muzolimine.
Xipamide Dihydroergocornine may decrease the antihypertensive activities of Xipamide.
Candesartan Dihydroergocornine may decrease the antihypertensive activities of Candesartan.
Tocopherylquinone Dihydroergocornine may decrease the antihypertensive activities of Tocopherylquinone.
Benazeprilat Dihydroergocornine may decrease the antihypertensive activities of Benazeprilat.
Fosinoprilat Dihydroergocornine may decrease the antihypertensive activities of Fosinoprilat.
Ramiprilat Dihydroergocornine may decrease the antihypertensive activities of Ramiprilat.
Perindoprilat Dihydroergocornine may decrease the antihypertensive activities of Perindoprilat.
Quinaprilat Dihydroergocornine may decrease the antihypertensive activities of Quinaprilat.
Furosemide Dihydroergocornine may decrease the antihypertensive activities of Furosemide.
Enalapril Dihydroergocornine may decrease the antihypertensive activities of Enalapril.
Amlodipine Dihydroergocornine may decrease the antihypertensive activities of Amlodipine.
Nimodipine Dihydroergocornine may decrease the antihypertensive activities of Nimodipine.
Lercanidipine Dihydroergocornine may decrease the antihypertensive activities of Lercanidipine.
Indapamide Dihydroergocornine may decrease the antihypertensive activities of Indapamide.
Nitrendipine Dihydroergocornine may decrease the antihypertensive activities of Nitrendipine.
Guanethidine Dihydroergocornine may decrease the antihypertensive activities of Guanethidine.
Bepridil Dihydroergocornine may decrease the antihypertensive activities of Bepridil.
Ambrisentan Dihydroergocornine may decrease the antihypertensive activities of Ambrisentan.
Pinacidil Dihydroergocornine may decrease the antihypertensive activities of Pinacidil.
Riociguat Dihydroergocornine may decrease the antihypertensive activities of Riociguat.
Macitentan Dihydroergocornine may decrease the antihypertensive activities of Macitentan.
Aliskiren Dihydroergocornine may decrease the antihypertensive activities of Aliskiren.
Lacidipine Dihydroergocornine may decrease the antihypertensive activities of Lacidipine.
Niguldipine Dihydroergocornine may decrease the antihypertensive activities of Niguldipine.

Target Protein

Serotonin Receptors HTR1A
Beta adrenergic receptor ADRB1
Alpha adrenergic receptor ADRA1A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15415441
    HAFKENSCHIEL JH, CRUMPTON CW, MOYER JH, JEFFERS WA, FISHEL HANLEY B, CONLIN HARNED S: The effects of dihydroergocornine on the cerebral circulation of patients with essential hypertension. J Clin Invest. 1950 Apr;29(4):408-11. doi: 10.1172/JCI102273.
  • PMID: 15395942
    FREIS ED, STANTON JR, et al.: The hemodynamic effects of hypotensive drugs in man; dihydroergocornine. J Clin Invest. 1949 Nov;28(6 Pt 2):1387-1402. doi: 10.1172/JCI102204.
  • PMID: 18731688
    Bercel NA: TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives. Calif Med. 1950 Apr;72(4):234-8.
  • PMID: 16695718
    Hayes DW, Wakim KG, Horton BT, Peters GA: THE EFFECTS OF DIHYDROERGOCORNINE ON THE CIRCULATION IN THE EXTREMITIES OF MAN. J Clin Invest. 1949 Jul;28(4):615-20. doi: 10.1172/JCI102111.
  • PMID: 18152249
    FLORMAN AL, FISCHER AE, MOLOSHOK RE: An evaluation of the mumps skin-test in pediatric practice. Bull N Y Acad Med. 1949 Jul;25(7):441.
  • PMID: 7063048
    Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33.
Textbook
  • ISBN: 0-12-260807-0
    Florey K. (1978). Analytical profiles of drug substances (7th ed.). Academic Press.
  • ISBN: 978-3-642-66777-0
    Berde B. and Schild H. (1978). Ergot alkaloids and related compounds. Springer-Verlag.
  • ISBN: 978-0-470-33447-4
    Barceloux D. (2008). Medical toxicology of natural substances. Wiley.
  • Preston S. (1917). Endocrinology. Williams & Wilkins Co..

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet, orally disintegrating • - • Oral • US • Generic • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul